The prevalence of human papilloma virus (HPV)-16 in patients with
cervical cancer, the physical status of HPV-16 in patients with cervical lesions, and the role of HPV-16 integration in cervical
carcinogenesis were investigated. HPV genotyping was performed by using PCR approach with the primer GP5+/GP6+ and type-specific primer on biopsy specimens taken operatively from 198 women. Multiple PCR was done to detect physical status of HPV-16 in a series of cervical liquid-based cytology samples and biopsy specimens obtained from different cervical lesions with HPV-16
infection, including 112 specimens with
cervical cancer, 151 specimens with CIN I, 246 specimens with CIN and 120 specimens with CINIII. The results showed that there were 112
cervical cancer samples (56.57% of total
cervical cancer patients) with HPV-16
infection. The frequency of HPV-16 pure integration was 65.18% (73/112), 56.57% (47/120), 23.58% (58/246) and 7.95% (12/151) in
cervical cancer, CINIII, CINII and CINI patients respectively. In situ hybridization was performed on some
paraffin-embedded sections of CINII, CINIII and
cervical cancer to verify the physical status of HPV-16
infection. Significant difference was observed between
cervical cancer and CIN I, CINII, CINIII in the frequency of HPV-16 integration (P<0.01). It is suggested that HPV-16 is the most prevalent type and is associated with
cervical cancer. In the case of HPV-16
infection there are close associations between the severity of cervical lesions and the frequency of HPV-16 integration. The application of testing HPV genotyping and physical status based on detection of HC-II HPV
DNA would be in favor of predicting the prognosis of cervical precancerosis and enhancing the screening accuracy of
cervical cancer.